Liver Disorders News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Pandion Therapeutics launches with $58M series A - FierceBiotech



Boston Business Journal
 
Pandion Therapeutics launches with $58M series A 
FierceBiotech
Pandion will first target inflammatory bowel disease and autoimmune liver disease, before expanding into autoimmune kidney disorders and Type 1 diabetes. Pandion expects to advance the pipeline, move into the clinic and demonstrate clinical efficacy ...
Pandion raises $58M for its autoimmune platform inspired by the tumor microenvironment MedCity News
Biogen, Pfizer vets launch autoimmune disease startup backed by $58M Boston Business Journal

all 10 news articles » 


Early warning score accurately predicts mortality risk in liver disease - Healio



Early warning score accurately predicts mortality risk in liver disease 
Healio
The National Early Warning Score accurately identified patients with chronic liver diseases at risk for death, admission to the intensive care unit or cardiac arrest within a 24-hour period, according to a recently published study. ?Hospitalized ...

 


Liver disease expert Dr. Andrew Feranchak joins Children's Hospital of Pittsburgh of UPMC - Tribune-Review



Liver disease expert Dr. Andrew Feranchak joins Children's Hospital of Pittsburgh of UPMC 
Tribune-Review
Dr. Andrew Feranchak, a liver disease expert, has been appointed chief of the division of pediatric gastroenterology, hepatology and nutrition at Children's Hospital of Pittsburgh of UPMC. A Pittsburgh native, Feranchak comes from the University of ...

 


Fatty Liver Disease Common in Spinal-Bulbar Muscular Atrophy - Neurology Advisor



Neurology Advisor
 
Fatty Liver Disease Common in Spinal-Bulbar Muscular Atrophy 
Neurology Advisor
Patients with spinal-bulbar muscular atrophy (SBMA) are at high risk for nonalcoholic liver disease as well as elevated glucose, serum triglycerides, and insulin, according to study findings published in Neurology. The investigators of this study ...

 


The Race To Find A Treatment For NASH - Nasdaq.com - Nasdaq



The Race To Find A Treatment For NASH - Nasdaq.com 
Nasdaq
(RTTNews.com) - The incidence of non-alcoholic steatohepatitis, or NASH, which refers to liver inflammation due to fat buildup in the liver, has risen dramatically over the last two decades because of growing prevalence of obesity, insulin resistance ...

and more » 


Pancreatic Conference, Liver Disorders,Gastroenterology Meeting - pharmaphorum



Pancreatic Conference, Liver Disorders,Gastroenterology Meeting 
pharmaphorum
PULSUS Conferences invites all the participants from all over the world to attend ?3rd International Conference on Pancreatic Cancer and Liver Diseases? under the theme ?Making Life Better: Fight Against Pancreatic Cancer and Liver Diseases? during ...

 


uniQure Aims to Begin First Human Trial of Investigational Gene Therapy AMT-130 for Huntington's in 2018 - Huntington's Disease News



Huntington's Disease News
 
uniQure Aims to Begin First Human Trial of Investigational Gene Therapy AMT-130 for Huntington's in 2018 
Huntington's Disease News
Additionally, the company is developing its gene therapy pipeline for other diseases: AMT-12 for congestive heart failure, and AMT-061 for hemophilia B. ?We also are intensifying efforts to further expand our gene therapy product pipeline. In addition ...

and more » 


In The Spotlight: Immuron Ltd. - Nasdaq.com - Nasdaq



In The Spotlight: Immuron Ltd. - Nasdaq.com 
Nasdaq
The American Depositary Shares of Immuron Limited have gained nearly 33% in the last 5 trading days. Immuron, an Australian biopharmaceutical.

and more » 


Scientists reveal secrets of 'anti-aging' hormones - FierceBiotech



FierceBiotech
 
Scientists reveal secrets of 'anti-aging' hormones 
FierceBiotech
They believe their findings could lead to new treatments for kidney and heart disease. Joseph Schlessinger, senior author of the Yale study and chair of pharmacology at its medical school, is leading a team that's exploring ways to both enhance and ...
Goddess protein could be a gift for medicine, study shows BT.com

all 5 news articles » 


Reviewing CytomX Therapeutics (CTMX) & Galmed Pharmaceuticals (GLMD) - The Lincolnian Online



Reviewing CytomX Therapeutics (CTMX) & Galmed Pharmaceuticals (GLMD) 
The Lincolnian Online
The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product ...

and more »